Dnth at Guggenheim healthcare conference: cash, pipeline and ambition

Monte Rosa Therapeutics (GLUE) showcased its broad clinical strategy at the 3rd Annual Guggenheim Healthcare Innovation Conference, targeting inflammation, cardiometabolic disease, and oncology. The biotech, seven years old, has moved past doubts about molecular glue degraders outside cancer, with NEK7 program showing early promise in inflammatory biomarker suppression for atherosclerotic cardiovascular disease and gout.

Monte Rosa's partnership with Novartis around VAV1 has generated $87.5 million in milestones, with no phase II development costs for the company. The company highlighted early oncology data for MRT-2359, noting a 100% PSA response rate in prostate cancer. Management believes the next 12 to 18 months could bring multiple readouts and trial starts across the pipeline, including gout, hidradenitis suppurativa, and additional Novartis studies.

Brief written by urgent.news from Investing.com's own syndicated text. Machine-written — may contain errors; check the original before relying on it.